Currently, Robinhood investors are betting that the coronavirus vaccine race is favoring the stocks of two obvious leaders: modern (Nasdaq stock code: MRNA) with Pfizer (New York Stock Exchange: PFE). They are among the top 100 most common investments in the portfolio using online trading platforms.
Robinhood investors are known for their tendency to look for stocks with greater volatility potential-coronavirus stocks are frequently delivered. Just this week, Moderna and Pfizer each rose by more than 7% in a single trading session, and the latter reported a positive mid-term effect of its Phase 3 trial of its COVID-1
However, Robinhood’s top 100 list lacks a name with great potential: Novax (Nasdaq stock code: NVAX). Of course, from a timeline perspective, the company lags behind Moderna and Pfizer. However, if its Phase III clinical trial results are positive, there are other factors that can make it a market leader.
As with Moderna and Pfizer’s drug candidates, preliminary data on Novavax’s potential vaccines are encouraging. In its phase 1 study, participants between the ages of 18 and 59 produced neutralizing antibody levels that were 4 to 6 times higher than those found in recovered coronavirus patients. Neutralizing antibodies are important because their role is to prevent infection. Novavax has not yet reported data on the elderly population, but we should get more information on vaccine performance in a wider age range as soon as possible-the company hopes the interim data of its UK Phase 3 trial (which includes 84-year-old participants) early in the first quarter (End of May).Since we are still waiting for information about the fares of candidates in the seniors cohort, it can be said that from the early data point of view, the result of Novavax is almost On par with competitors’ plans.
However, compared with its competitors, Novavax stands out in three respects. The first is related to future plans.
Novavax’s goal is to use its expertise in flu prevention to explore flu/COVID-19 combination vaccines. The company’s NanoFlu vaccine candidate product reached its main goal in a key trial this year, so the next step in this regard will be to submit an application to the regulatory agency for approval. But the company has formed a research team to study the combination of NanoFlu and coronavirus vaccine candidates.
Any such potential dual vaccine will be used after the pandemic. Considering the severity of the current health crisis, countries and people are likely to want to continue their efforts to protect their health in the future. Therefore, it is wise to develop a product designed to prevent further outbreaks after the pandemic is under control. It is also smart to target compound vaccines. After all, who likes lenses? Two-in-one clubs are very popular. It can also simplify transportation and storage, thereby reducing costs.
More than 2 billion doses
Another highlight of Novavax is production capacity. Taking into account the demand for vaccines, every dose that can be produced will be welcomed. But those companies that can mass produce vaccines will undoubtedly have the potential to occupy more available markets. Novavax expects to have sufficient online capacity by mid-2021 to produce more than 2 billion doses of vaccine each year. In contrast, Pfizer’s goal is to produce 1.3 billion doses by the end of next year. Moderna’s goal is to deliver 500 million to 1 billion units next year.
Finally, Novavax may benefit from logistics factors. Its vaccine can be stored between 35 and 46 degrees Fahrenheit. For many of us, this is common fall or winter weather, which means the vaccine can be transported in a standard refrigerated truck and can be stored in a regular refrigerator. Moderna’s vaccine requires a temperature of minus 4 degrees Fahrenheit, while Pfizer’s vaccine needs to be transported at an ultra-cold temperature of minus 94 degrees Fahrenheit. These requirements will make storage and transportation more challenging.
Therefore, yes, Pfizer and Moderna are in the lead from the timetable. Both of their candidates can meet FDA requirements, which will enable the two companies to apply for emergency use authorization (EUA) later this month. If the US Food and Drug Administration provides EUA to one or two companies, they and their shareholders will benefit. But Novavax’s strength can still make it a long-term, long-term winner in the COVID-19 vaccine race. This is why Robinhood investors and other activist investors should now consider adding Novavax stock to their portfolio.